LRPPRC Antikörper (FITC)
Kurzübersicht für LRPPRC Antikörper (FITC) (ABIN1400234)
Target
Alle LRPPRC Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Kreuzreaktivität
- Human, Maus, Ratte
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human LRP130
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- IF(IHC-P) 1:50-200
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- LRPPRC (Leucine-Rich PPR-Motif Containing (LRPPRC))
-
Andere Bezeichnung
- LRP130
-
Hintergrund
-
Synonyms: LRPPRC, 130 kDa leucine-rich protein, GP130, Leucine-rich PPR-mot containing protein, LRP 130, LPPRC_HUMAN.
Background: Leucine-rich protein (LRP130) is a cytoplasmic mRNA-binding protein likely to be involved in the processing of mitochondrial DNA transcripts. Defects in the LRPPRC gene that encodes LRP130 result in the French-Canadian type of Leigh syndrome, a severe neurological disorder characterized by lesions in the subcortical region of the brain. LRP130 also interacts with the low-affinity receptor for leukemia inhibitory factor to produce an intracelluar signal cascade.
Target
-